At this time, the firm appears to be overvalued. Medacta Group SA secures a last-minute Real Value of USD130.77 per share. The latest price of the firm is USD148.6. Our model forecasts the value of Medacta Group SA from analyzing the firm fundamentals such as Profit Margin of 0.15 %, return on equity of 0.25, and Current Valuation of 2.96 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Medacta Group's valuation include:
Price Book
7.6006
Enterprise Value
3 B
Enterprise Value Ebitda
16.7238
Price Sales
4.5874
Forward PE
30.7692
Overvalued
Today
148.60
Please note that Medacta Group's price fluctuation is very steady at this time. Calculation of the real value of Medacta Group SA is based on 3 months time horizon. Increasing Medacta Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Medacta stock is determined by what a typical buyer is willing to pay for full or partial control of Medacta Group SA. Since Medacta Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medacta Stock. However, Medacta Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical
Market 148.6
Real 130.77
Hype 148.63
The intrinsic value of Medacta Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medacta Group's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medacta Group SA helps investors to forecast how Medacta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medacta Group more accurately as focusing exclusively on Medacta Group's fundamentals will not take into account other important factors:
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Medacta Group's intrinsic value based on its ongoing forecasts of Medacta Group's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Medacta Group's closest peers.
Medacta Group Cash
29.39 Million
Medacta Group Total Value Analysis
Medacta Group SA is now anticipated to have takeover price of 2.96 B with market capitalization of 2.96 B, debt of 241.21 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medacta Group fundamentals before making investing decisions based on enterprise value of the company
About 70.0% of the company outstanding shares are owned by corporate insiders. The company last dividend was issued on the 9th of May 2025. Based on the analysis of Medacta Group's profitability, liquidity, and operating efficiency, Medacta Group SA is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medacta Group has an asset utilization ratio of 74.55 percent. This indicates that the Company is making USD0.75 for each dollar of assets. An increasing asset utilization means that Medacta Group SA is more efficient with each dollar of assets it utilizes for everyday operations.
Yuan Drop
Covid
Interest Hikes
Medacta Group Profitability Analysis
Considering Medacta Group's profitability and operating efficiency indicators, Medacta Group SA is yielding more profit at this time then in previous quarter. It has a moderate probability of reporting better profitability numbers in March. Profitability indicators assess Medacta Group's ability to earn profits and add value for shareholders.
Net Income
First Reported
2015-12-31
Previous Quarter
34.9 M
Current Value
60 M
Quarterly Volatility
13.1 M
Yuan Drop
Covid
Interest Hikes
At this time, Medacta Group's Pretax Profit Margin is fairly stable compared to the past year. Operating Profit Margin is likely to climb to 0.19 in 2026, whereas Gross Profit is likely to drop slightly above 281.5 M in 2026.
For Medacta Group profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medacta Group SA to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medacta Group utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medacta Group's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medacta Group over time as well as its relative position and ranking within its peers.
Medacta Group Earnings per Share Projection vs Actual
By analyzing Medacta Group's earnings estimates, investors can diagnose different trends across Medacta Group's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Medacta Group SA is based on EPS before non-recurring items and includes expenses related to employee stock options.
Covid
Interest Hikes
Medacta Group is projected to generate 0.7275 in earnings per share on the 31st of December 2023. Medacta Group earnings estimates show analyst consensus about projected Medacta Group EPS (Earning Per Share). It derives the highest and the lowest estimates based on Medacta Group's historical volatility. Many public companies, such as Medacta Group, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.
Medacta Group Ownership Allocation
Medacta Group SA maintains a total of 19.94 Million outstanding shares. Medacta Group SA secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 69.64 % of Medacta Group SA outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Medacta Group Profitability Analysis
The company reported the revenue of 590.58 M. Net Income was 72.89 M with profit before overhead, payroll, taxes, and interest of 436.82 M.
About Medacta Group Valuation
Our relative valuation model uses a comparative analysis of Medacta Group. We calculate exposure to Medacta Group's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medacta Group's related companies.
When running Medacta Group's price analysis, check to measure Medacta Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medacta Group is operating at the current time. Most of Medacta Group's value examination focuses on studying past and present price action to predict the probability of Medacta Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medacta Group's price. Additionally, you may evaluate how the addition of Medacta Group to your portfolios can decrease your overall portfolio volatility.